Based on the poor outcome observed in studies that evaluated AML with RUNX1 mutations, the 2016 revised WHO AML classification system regards de novo AML with mutated RUNX1 as a provisional entity (57, 69, 70). Here, RUNX1 is linked to acute myeloid leukemia.